9 Results for "

EGFR-driven

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "EGFR-driven" in MCE Product Catalog:

Cat. No.: HY-178861
Research Areas:  

Cancer

dCDK9-202 a potent CDK9 PROTAC degrader with an DC50 value of 3.5 nM. dCDK9-202 exhibits broad-spectrum anti-tumor activity and extensively disrupts the oncogenic transcriptome. dCDK9-202 can activate Caspase-3/7, increase the level of cleaved PARP, and directly induce apoptosis of tumor cells. dCDK9-202 effectively inhibits TC-71 tumor growth without any signs of toxicity in mice. dCDK9-202 can be used for the study of EGFR-driven cancers such as sarcoma (Pink: CDK9 ligand (HY-178862); Blue: CRBN ligand (HY-W248665); Black: Linker (HY-N8015)) .
loading...
    loading...
Cat. No.: HY-W423595
CAS No.: 2050906-40-4
Target:  

EGFR

Research Areas:  

Cancer

BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research .
loading...
    loading...
Cat. No.: HY-178242
CAS No.: 2654821-07-3
Target:  

PROTACs EGFR

Research Areas:  

Cancer

PROTAC EGFR degrader 16 (Compound 98) a selective EGFR PROTAC degrader with DC50 values of < 50 nM in NCI-H1975 (EGFR L858R-T970M), NCI-H3225 (EGFR L858R) and NCI-H1976 + CS (EGFR L858R-T970M-L797S). PROTAC EGFR degrader 16 can be used for the study of EGFR-driven cancerssuch as non-small cell lung cancer (Pink: EGFR ligand (HY-178313); Blue: CRBN ligand (HY-W1128702); Black: Linker; EGFR ligand + Linker (HY-178311)) .
loading...
    loading...
Cat. No.: HY-123952
CAS No.: 1423077-49-9
Purity:  99.89%
Synonyms: TRC-382
Target:  

EGFR

Research Areas:  

Cancer

RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling .
loading...
    loading...
Cat. No.: HY-P991092

Target:  

EGFR CD276/B7-H3

Research Areas:  

Cancer

IBI-334 is a bispecific B7-H3 and EGFR antibody. IBI-334 has an EGFR arm for signal blockage and is coupled with a fine-tuned B7-H3 arm with optimal affinity and binding domain. IBI-334 shows antibody-mediated cell cytotoxicity (ADCC) effects. IBI-334 has a wide range of applications in many EGFR-driven solid tumors .
loading...
    loading...
Cat. No.: HY-125102
CAS No.: 851432-37-6
Target:  

IGF-1R

Research Areas:  

Cancer

AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC50 of 17 nmol/L. The IC50 for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.
loading...
    loading...
Cat. No.: HY-116091
CAS No.: 220576-72-7
Target:  

EGFR Akt ERK

Research Areas:  

Cancer

EGFR-IN-451 is an EGFR inhibitor with an IC50 value of 0.02 nM. EGFR-IN-451 also inhibits mutant EGFR L858R, EGFR T790M, and EGFR L858R/T790M with IC50 values of 0.26-34 nM. EGFR-IN-451 inhibits AKT and ERK activation and inhibits proliferation of EGFR-mutant cancer cells. EGFR-IN-451 can be used for the research of EGFR-driven cancer .
loading...
    loading...
Cat. No.: HY-158969
CAS No.: 2549192-10-9
Target:  

EGFR Apoptosis Akt ERK

Research Areas:  

Cancer

EGFR-IN-113 (compound II-1) is an EGFR kinase inhibitor with an IC50 of 14.79 μM. EGFR-IN-113 can induce apoptosis and inhibit cell proliferation by downregulating Akt and Erk1/2 signaling. EGFR-IN-113 can be used for research in EGFR-driven cancers, such as lung cancer, pancreatic cancer, and breast cancer .
loading...
    loading...
Cat. No.: HY-P991092A

Target:  

EGFR CD276/B7-H3

Research Areas:  

Cancer

IBI-334 (FUT8-KO) is a bispecific B7-H3 and EGFR antibody that has knocked out the fucosyltransferase 8 gene (FUT8). IBI-334 (FUT8-KO) has an EGFR arm for signal blocking and is coupled with a fine-tuned B7-H3 arm with the best affinity and binding domain. IBI-334 (FUT8-KO), compared to IBI-334 (HY-P991092), has enhanced antibody-mediated cytotoxicity (ADCC) effect. IBI-334 (FUT8-KO) has wide applications in many EGFR-driven solid tumors .
loading...
    loading...